$BRNS News

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments

Barinthus Biotherapeutics Q2 EPS $(0.26) Beats $(0.30) Estimate

Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments

Barinthus Biotherapeutics Q1 EPS $(0.14) Beats $(0.30) Estimate

Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments

Barinthus Biotherapeutics Q4 EPS $(0.27) Beats $(0.40) Estimate

Barinthus Biotherapeutics Receives Nasdaq Noncompliance Notification, Gets Time Through June 20 To Regain Compliance

Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Buy: What Does It Mean for the Stock?

Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

Barinthus Bio Issues Update On First-In-Human Phase 1 Trial Of VTP-1000 In Adults With Celiac Disease

HC Wainwright & Co. Maintains Buy on Barinthus Biotherapeutics, Raises Price Target to $4

Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments

Barinthus Biotherapeutics Q3 EPS $(0.36) Beats $(0.45) Estimate, Sales $14.969M, Same YoY

ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics

ChemDiv To Continue R&D Support As Clywedog Merges With Barinthus Therapeutics; Combined Entity To Trade Under Ticker CLYD On Nasdaq

Trading Halt: Halt status updated at 8:15:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending

Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases

Barinthus Biotherapeutics And Clywedog Therapeutics Enters Into A Definitive All-Stock Merger Agreement To Form Combined Company; Before Transaction Closes The Combined Company May Initiate Partial Tender Offer To Purchase Up To $27M Worth Of Its Outstanding Shares Held By Barinthus Bio Shareholders